Stockscreener 앱 받기
4.58
1.72%
-0.08
시장 영업 전:
4.66
0.08
+1.75%
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics, Inc. (IRD) reports Q4 loss, tops revenue estimates - MSN
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells 2,816 Shares of Stock - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells $19,041.28 in Stock - MarketBeat
Opus Genetics COO Schachle sells $19,525 in stock By Investing.com - Investing.com South Africa
Opus Genetics COO Schachle sells $19,525 in stock - Investing.com
Insider Selling: Opus Genetics (NASDAQ:IRD) CEO Sells 24,438 Shares of Stock - MarketBeat
Opus Genetics chief scientific officer sells $19k in stock - Investing.com
Opus Genetics (IRD) officer has 2,816 shares sold to cover tax - Stock Titan
Opus Genetics (IRD) CEO has shares sold automatically to cover RSU taxes - Stock Titan
Opus Genetics (IRD) CSO has shares sold automatically for tax withholding - Stock Titan
Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN
Aug Catalysts: Can Opus Genetics Inc reach all time highs this yearMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Oppenheimer initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Up 17.9% in February - MarketBeat
Opus Genetics (IRD) Initiates Coverage with Outperform Rating by Oppenheimer | IRD Stock News - GuruFocus
Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD) - MarketBeat
Oppenheimer Analyst Initiates Coverage on Opus Genetics (IRD) wi - GuruFocus
Oppenheimer Initiates Opus Genetics at Outperform With $10 Price Target - marketscreener.com
There's Reason For Concern Over Opus Genetics, Inc.'s (NASDAQ:IRD) Massive 26% Price Jump - 富途牛牛
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Biotechnology company Opus Genetics Inc recently filed documents with the U.S. Securities and Exchange Commission (SEC) to officially register 7.4 million shares of common stock for secondary market resale. - Bitget
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
HC Wainwright Has Negative View of Opus Genetics Q1 Earnings - MarketBeat
Lifesci Capital Forecasts Lower Earnings for Opus Genetics - MarketBeat
BTIG raises its price target on Opus Genetics, Inc. (IRD) to $12 from $7 and maintains a buy rating - MSN
Opus Genetics, Inc. 2025 Annual Report: Gene Therapy Pipeline, Clinical Progress, and Strategic Partnerships in Ophthalmology - Minichart
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch - TipRanks
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Opus Genetics (NASDAQ:IRD) Given New $10.00 Price Target at Wedbush - MarketBeat
Opus Genetics (NASDAQ:IRD) Stock Price Expected to Rise, Chardan Capital Analyst Says - MarketBeat
Opus Genetics (IRD) Target Price Raised by Wedbush Analyst | IRD Stock News - GuruFocus
Chardan Capital Raises Price Target for Opus Genetics (IRD) to $11 | IRD Stock News - GuruFocus
Opus Genetics (IRD) Gets a Buy from H.C. Wainwright - The Globe and Mail
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating - Insider Monkey
IRD Technical Analysis | Trend, Signals & Chart Patterns | OPUS GENETICS INC (NASDAQ:IRD) - ChartMill
Craig-Hallum Maintains Buy on Opus Genetics (IRD) March 2026 - Meyka
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA) - The Globe and Mail
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target By Investing.com - Investing.com India
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target - Investing.com South Africa
Opus Genetics (IRD) Trailing US$49.6m Loss Reinforces Bearish Profitability Narrative - Sahm
Opus Genetics Inc. (IRD) Reports FY25 Earnings - AlphaStreet
Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M - AlphaStreet
Opus Genetics, Inc. (IRD) Announces Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Opus Genetics (IRD) Exceeds Revenue Projections and Advances Gen - GuruFocus
Earnings Summary: Opus Genetics Q4 - Benzinga
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - The Manila Times
Craig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - MSN
Opus Genetics (IRD) Price Target Increased by 13.45% to 7.87 - MSN
Is Opus Genetics Inc. stock near bottom after declineQuarterly Growth Report & Smart Swing Trading Alerts - Naître et grandir
Market Recap: Can Opus Genetics Inc benefit from deglobalizationQuarterly Investment Review & Stock Portfolio Risk Control - baoquankhu1.vn
IRD Should I Buy - Intellectia AI
RTP firm looks to expand market for eye-drop treatment - The Business Journals
Where Opus Genetics Stands With Analysts - Sahm
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - The Manila Times
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Concentra Group Holdings Parent, Inc. (CON) and Opus Genetics (IRD) - The Globe and Mail
1.20%
0.06%
자본화:
|
볼륨(24시간):